Antiviral hyperactivation-limiting therapeutics as a novel class for the treatment of HIV/AIDS: focus on VS411

Author： Uglietti Alessia   Maserati Renato  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.20, Iss.4, 2011-04, pp. : 559-565

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Nanomedicines as Therapeutics in HIV-AIDS

By  

Pharmaceutical Nanotechnology, Vol. 4, Iss. 4, 2016-12 ,pp. : 255-266

Bentham Science Publishers

Access to resources Recommend Favorite

Etravirine for the treatment of HIV/AIDS

By Schrijvers Rik  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 8, 2013-06 ,pp. : 1087-1096

Informa Healthcare

Access to resources Recommend Favorite

The HIV/AIDS Treatment Directory is now available online

By  

Inpharma, Vol. 1, Iss. 1220, 2000-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite

The Cost Effectiveness of Antiretroviral Regimens for the Treatment of HIV/AIDS

By Anis A.H.  

PharmacoEconomics, Vol. 18, Iss. 4, 2000-10 ,pp. : 393-404

Adis International

Access to resources Recommend Favorite

UN initiatives for HIV/AIDS treatment programmes

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 445, 2004-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite